Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-8: belantamab mafodotin + pomalidomide + dexamethasone versus pomalidomide + bortezomib + dexamethasone in relapsed/refractory multiple myeloma
MOH_2021-01-28_009705Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoint: Primary endpoint not specified in registry entry. Started Dec 2020; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2021-01-28_009705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-28_009705.